CytomX Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in South San Francisco, California, dedicated to transforming the treatment of cancer through its proprietary Probody™ technology platform. This technology enables the development of highly selective therapeutics designed to minimize off-tumor effects while maximizing anti-tumor activity, thus addressing significant unmet medical needs in oncology. With a robust pipeline of product candidates in various stages of clinical development, CytomX aims to enhance patient outcomes and redefine cancer treatment paradigms. The company is strategically positioned to leverage its cutting-edge technology for potential partnerships and collaborations, further expanding its reach within the biopharmaceutical landscape.